English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 905962      Online Users : 581
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/9642


    Title: JAK2 overexpression is a prognostic indicator for worse outcome in nasopharyngeal carcinoma and is independent of JAK2 exon 12 and JAK2 V617F mutation
    Authors: Liang, PI;Li, CF
    Contributors: National Institute of Cancer Research
    Abstract: Background: The nasopharyngeal carcinoma (NPC) has distinct incidence in various races and different geographical regions. It is endemic in southern China, Southeast Asia, and the Middle East. The etiology of NPC is likely multifactorial, which include genetic susceptibility, infection by Epstein-Barr virus (EBV), and environmental factors. There are several molecular pathways involved in the pathogenesis of NPC. JAK2 is one of the four members of the Janus kinase (JAK) family, and its mutation is an important oncogenic driver in myeloproliferative neoplasms and certain hematopoietic malignancies. By using public domain datasets and our well-characterized cohort, we intended to analyze the association of JAK2 expression in NPC. Design: Two datasets from GEO (GSE12452 and GSE34573) were used to analyze the significance of JAK2 transcript expression between tumor and non-tumor specimen. JAK2 immunostain was performed on 124 cases of NPC and interpreted using H-score. The result was then correlated with clinicopathological features, disease-specific survival (DSS), distal metastasis-free survival (DMeFS), and local recurrence-free survival (LRFS). Twenty NPC cases with JAK2 overexpression were also submitted for JAK2 exon 12 and JAK2 V617F mutation analyses using PCR followed by direct sequencing.Results: Validation of the datasets in public domain showed that, in contrast with non-tumor specimens, there is an up-regulation of JAK2 transcript in NPC. In the immunohistochemical study, JAK2 overexpression significantly associated with advanced disease stage (stage I-II vs stage III-IV, p = 0.019). Its overexpression also independently predict poor DSS (p =0.005), DMeFS (p =0.036), and LRFS (p =0.012). None of the 20 JAK2 overexpressed NPC cases have JAK2 exon 12 and JAK2 V617F mutation. Conclusions: JAK2 overexpression is associated with advanced disease stage and conferred poor clinical outcome, justifying that JAK2 is a potential prognostic biomarker of NPC. Its overexpression is also independent of JAK2 exon 12 and JAK2 V617F mutation.
    Date: 2016-02
    Relation: Modern Pathology. 2016 Feb;29(Suppl. 2):325A.
    Link to: http://www.nature.com/modpathol/journal/v29/n2s/pdf/modpathol201612a.pdf
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0893-3952&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000370302502299
    Appears in Collections:[其他] 會議論文/會議摘要

    Files in This Item:

    File Description SizeFormat
    ISI000370302502299.pdf245KbAdobe PDF380View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback